A new drug combination may benefit men whose prostate cancer has returned after primary surgery or radiation therapy. Pairing enzalutamide, an androgen receptor blocker, with the hormone therapy drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results